Another Vaccine Now in the Final Stages of Testing


Months into the pandemic, more companies are entering the final stages of vaccine testing.

Just over the last few days, Novavax (NVAX) said it would start its Phase 3 trial among 30,000 people in the UK.  In additional, a trial of 30,000 could begin in the U.S. if regulators are pleased with the safest of a Phase 2 trial under way at the moment, according to Barron’s.

The latest study in the UK will track whether adults receiving a two-dose vaccine see a lower rate of symptomatic COVID, as compared to those receiving the placebo.

Other than Novavax, Johnson & Johnson has Phase 3 trials under way, too.

The company expects results of its Phase 3 trials by the close of this year, or early 2021.  If successful, it could manufacture up to a billion doses in the new year.  In addition, unlike its competition, Johnson & Johnson’s vaccine may only require one dose of the vaccine.

“The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control,” Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine, as quoted by Reuters.



Please enter your comment!
Please enter your name here